Moleac logo.png
Moleac’s NeuroAiD™II Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain Injury
December 04, 2023 22:41 ET | Moleac Pte Ltd
Promising results from the SAMURAI study show NeuroAiDTMII significantly improves post-concussion symptoms, QoL and mood post-mild traumatic brain injury.
Incannex Healthcare Announces Completion of its Redomiciliation to the United States
November 29, 2023 13:40 ET | Incannex Healthcare
MELBOURNE, Australia and NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ: IXHL) is pleased to announce that its previously announced transaction to redomicile Incannex...
Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC
November 16, 2023 08:30 ET | Incannex Healthcare
MELBOURNE, Australia, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL) (the “Company” or “Incannex”) is pleased to announce that the Federal Court of Australia...
Post-acute Care Market Worth $1.37 Billion, Globally, Billion by 2030 - Exclusive Report by The Insight Partners
October 26, 2023 07:36 ET | The Insight Partners
Pune, India, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Post-acute care encompasses a broad range of services the patient gets after hospitalization. Sometimes, these services are provided as an alternative...
Aviv-Clinic Logo.png
Aviv Clinics Highlights New Literature Review Sharing the Efficacy of Hyperbaric Oxygen Therapy for Traumatic Brain Injury Patients
August 01, 2023 13:24 ET | Aviv Clinics
ORLANDO, Fla., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Aviv Clinics, one of the most advanced brain clinics in the world, shares the results of a new comprehensive literature review that shows hyperbaric...
Algernon Logo 1.png
Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies
June 05, 2023 07:00 ET | Algernon Pharmaceuticals
VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Neuronic and Santa Clara University partner to develop next-gen neurotech for photobiomodulation guided by real-time brain activity
May 11, 2023 12:00 ET | Neuronic Devices Operations GmbH
Integrating photobiomodulation with neurofeedback will revolutionize treatment of brain disorders SANTA CLARA, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Neuronic, a multi-national company focused...
Algernon Logo 1.png
Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M
April 03, 2023 07:00 ET | Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 03, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Telesis Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Guidance
March 21, 2023 16:05 ET | Telesis Bio
-- Record revenue of $9.5M in 4QFY22; Increase of 208% over 4QFY21 -- BioXp® Revenue increased by 158% to $3.4M, in 4QFY22 over 4QFY21 SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Telesis Bio...
New Logo.jpg
Social Life Network Announces Name Change on OTC Markets to Decentral Life, Inc.
February 03, 2023 13:11 ET | Decentral Life, Inc
GREENWOOD VILLAGE, CO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Decentral Life, Inc. (OTC: WDLF), a Technology Business Incubator (TBI), previously named Social Life Network, Inc., is pleased to announce...